Author: "Matheson, Nicholas J" - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Matheson, Nicholas J"' showing total 258 results

Start Over Author "Matheson, Nicholas J"

258 results on '"Matheson, Nicholas J"'

1. Age-associated B cells predict impaired humoral immunity after COVID-19 vaccination in patients receiving immune checkpoint blockade

Author: Yam-Puc, Juan Carlos, Hosseini, Zhaleh, Horner, Emily C., Gerber, Pehuén Pereyra, Beristain-Covarrubias, Nonantzin, Hughes, Robert, Lulla, Aleksei, Rust, Maria, Boston, Rebecca, Ali, Magda, Fischer, Katrin, Simmons-Rosello, Edward, O’Reilly, Martin, Robson, Harry, Booth, Lucy H., Kahanawita, Lakmini, Correa-Noguera, Andrea, Favara, David, Ceron-Gutierrez, Lourdes, Keller, Baerbel, Craxton, Andrew, Anderson, Georgina S. F., Sun, Xiao-Ming, Elmer, Anne, Saunders, Caroline, Bermperi, Areti, Jose, Sherly, Kingston, Nathalie, Mulroney, Thomas E., Piñon, Lucia P. G., Chapman, Michael A., Grigoriadou, Sofia, MacFarlane, Marion, Willis, Anne E., Patil, Kiran R., Spencer, Sarah, Staples, Emily, Warnatz, Klaus, Buckland, Matthew S., Hollfelder, Florian, Hyvönen, Marko, Döffinger, Rainer, Parkinson, Christine, Lear, Sara, Matheson, Nicholas J., and Thaventhiran, James E. D.
Published: 2023
Full Text: View/download PDF

2. Accelerated waning of the humoral response to COVID-19 vaccines in obesity

Author: van der Klaauw, Agatha A., Horner, Emily C., Pereyra-Gerber, Pehuén, Agrawal, Utkarsh, Foster, William S., Spencer, Sarah, Vergese, Bensi, Smith, Miriam, Henning, Elana, Ramsay, Isobel D., Smith, Jack A., Guillaume, Stephane M., Sharpe, Hayley J., Hay, Iain M., Thompson, Sam, Innocentin, Silvia, Booth, Lucy H., Robertson, Chris, McCowan, Colin, Kerr, Steven, Mulroney, Thomas E., O’Reilly, Martin J., Gurugama, Thevinya P., Gurugama, Lihinya P., Rust, Maria A., Ferreira, Alex, Ebrahimi, Soraya, Ceron-Gutierrez, Lourdes, Scotucci, Jacopo, Kronsteiner, Barbara, Dunachie, Susanna J., Klenerman, Paul, Park, Adrian J., Rubino, Francesco, Lamikanra, Abigail A., Stark, Hannah, Kingston, Nathalie, Estcourt, Lise, Harvala, Heli, Roberts, David J., Doffinger, Rainer, Linterman, Michelle A., Matheson, Nicholas J., Sheikh, Aziz, Farooqi, I. Sadaf, and Thaventhiran, James E. D.
Published: 2023
Full Text: View/download PDF

3. FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2

Author: Brevini, Teresa, Maes, Mailis, Webb, Gwilym J., John, Binu V., Fuchs, Claudia D., Buescher, Gustav, Wang, Lu, Griffiths, Chelsea, Brown, Marnie L., Scott, III, William E., Pereyra-Gerber, Pehuén, Gelson, William T. H., Brown, Stephanie, Dillon, Scott, Muraro, Daniele, Sharp, Jo, Neary, Megan, Box, Helen, Tatham, Lee, Stewart, James, Curley, Paul, Pertinez, Henry, Forrest, Sally, Mlcochova, Petra, Varankar, Sagar S., Darvish-Damavandi, Mahnaz, Mulcahy, Victoria L., Kuc, Rhoda E., Williams, Thomas L., Heslop, James A., Rossetti, Davide, Tysoe, Olivia C., Galanakis, Vasileios, Vila-Gonzalez, Marta, Crozier, Thomas W. M., Bargehr, Johannes, Sinha, Sanjay, Upponi, Sara S., Fear, Corrina, Swift, Lisa, Saeb-Parsy, Kourosh, Davies, Susan E., Wester, Axel, Hagström, Hannes, Melum, Espen, Clements, Darran, Humphreys, Peter, Herriott, Jo, Kijak, Edyta, Cox, Helen, Bramwell, Chloe, Valentijn, Anthony, Illingworth, Christopher J. R., Dahman, Bassam, Bastaich, Dustin R., Ferreira, Raphaella D., Marjot, Thomas, Barnes, Eleanor, Moon, Andrew M., Barritt, IV, Alfred S., Gupta, Ravindra K., Baker, Stephen, Davenport, Anthony P., Corbett, Gareth, Gorgoulis, Vassilis G., Buczacki, Simon J. A., Lee, Joo-Hyeon, Matheson, Nicholas J., Trauner, Michael, Fisher, Andrew J., Gibbs, Paul, Butler, Andrew J., Watson, Christopher J. E., Mells, George F., Dougan, Gordon, Owen, Andrew, Lohse, Ansgar W., Vallier, Ludovic, and Sampaziotis, Fotios
Published: 2023
Full Text: View/download PDF

4. SARS-CoV-2 evolution during treatment of chronic infection

Author: Baker, Stephen, Dougan, Gordon, Hess, Christoph, Kingston, Nathalie, Lehner, Paul J, Lyons, Paul A, Matheson, Nicholas J, Owehand, Willem H, Saunders, Caroline, Summers, Charlotte, Thaventhiran, James ED, Toshner, Mark, Weekes, Michael P, Bucke, Ashlea, Calder, Jo, Canna, Laura, Domingo, Jason, Elmer, Anne, Fuller, Stewart, Harris, Julie, Hewitt, Sarah, Kennet, Jane, Jose, Sherly, Kourampa, Jenny, Meadows, Anne, O’Brien, Criona, Price, Jane, Publico, Cherry, Rastall, Rebecca, Ribeiro, Carla, Rowlands, Jane, Ruffolo, Valentina, Tordesillas, Hugo, Bullman, Ben, Dunmore, Benjamin J, Fawke, Stuart, Gräf, Stefan, Hodgson, Josh, Huang, Christopher, Hunter, Kelvin, Jones, Emma, Legchenko, Ekaterina, Matara, Cecilia, Martin, Jennifer, Mescia, Federica, O’Donnell, Ciara, Pointon, Linda, Pond, Nicole, Shih, Joy, Sutcliffe, Rachel, Tilly, Tobias, Treacy, Carmen, Tong, Zhen, Wood, Jennifer, Wylot, Marta, Bergamaschi, Laura, Betancourt, Ariana, Bower, Georgie, Cossetti, Chiara, De Sa, Aloka, Epping, Madeline, Gleadall, Nick, Grenfell, Richard, Hinch, Andrew, Huhn, Oisin, Jackson, Sarah, Jarvis, Isobel, Lewis, Daniel, Marsden, Joe, Nice, Francesca, Okecha, Georgina, Omarjee, Ommar, Perera, Marianne, Richoz, Nathan, Romashova, Veronika, Yarkoni, Natalia Savinykh, Sharma, Rahul, Stefanucci, Luca, Stephens, Jonathan, Strezlecki, Mateusz, Turner, Lori, De Bie, Eckart MDD, Bunclark, Katherine, Josipovic, Masa, Mackay, Michael, Rossi, Sabrina, Selvan, Mayurun, Spencer, Sarah, Yong, Cissy, Ansaripour, Ali, Michael, Alice, Mwaura, Lucy, Patterson, Caroline, Polwarth, Gary, Polgarova, Petra, di Stefano, Giovanni, Fahey, Codie, Michel, Rachel, and Bong, Sze-How
Subjects: Immunization, Pneumonia & Influenza, Lung, Prevention, Genetics, Vaccine Related, Biotechnology, Pneumonia, Emerging Infectious Diseases, Biodefense, Infectious Diseases, 2.1 Biological and endogenous factors, Aetiology, Infection, Good Health and Well Being, Adenosine Monophosphate, Aged, Alanine, Antibodies, Neutralizing, Antibodies, Viral, COVID-19, Chronic Disease, Evolution, Molecular, Genome, Viral, High-Throughput Nucleotide Sequencing, Humans, Immune Evasion, Immune Tolerance, Immunization, Passive, Immunosuppression Therapy, Male, Mutagenesis, Mutant Proteins, Mutation, Phylogeny, SARS-CoV-2, Spike Glycoprotein, Coronavirus, Time Factors, Viral Load, Virus Shedding, COVID-19 Drug Treatment, COVID-19 Serotherapy, CITIID-NIHR BioResource COVID-19 Collaboration, COVID-19 Genomics UK (COG-UK) Consortium, General Science & Technology
Abstract: The spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is critical for virus infection through the engagement of the human ACE2 protein1 and is a major antibody target. Here we show that chronic infection with SARS-CoV-2 leads to viral evolution and reduced sensitivity to neutralizing antibodies in an immunosuppressed individual treated with convalescent plasma, by generating whole-genome ultra-deep sequences for 23 time points that span 101 days and using in vitro techniques to characterize the mutations revealed by sequencing. There was little change in the overall structure of the viral population after two courses of remdesivir during the first 57 days. However, after convalescent plasma therapy, we observed large, dynamic shifts in the viral population, with the emergence of a dominant viral strain that contained a substitution (D796H) in the S2 subunit and a deletion (ΔH69/ΔV70) in the S1 N-terminal domain of the spike protein. As passively transferred serum antibodies diminished, viruses with the escape genotype were reduced in frequency, before returning during a final, unsuccessful course of convalescent plasma treatment. In vitro, the spike double mutant bearing both ΔH69/ΔV70 and D796H conferred modestly decreased sensitivity to convalescent plasma, while maintaining infectivity levels that were similar to the wild-type virus.The spike substitution mutant D796H appeared to be the main contributor to the decreased susceptibility to neutralizing antibodies, but this mutation resulted in an infectivity defect. The spike deletion mutant ΔH69/ΔV70 had a twofold higher level of infectivity than wild-type SARS-CoV-2, possibly compensating for the reduced infectivity of the D796H mutation. These data reveal strong selection on SARS-CoV-2 during convalescent plasma therapy, which is associated with the emergence of viral variants that show evidence of reduced susceptibility to neutralizing antibodies in immunosuppressed individuals.
Published: 2021

5. Screening in serum-derived medium reveals differential response to compounds targeting metabolism

Author: Abbott, Keene L., Ali, Ahmed, Casalena, Dominick, Do, Brian T., Ferreira, Raphael, Cheah, Jaime H., Soule, Christian K., Deik, Amy, Kunchok, Tenzin, Schmidt, Daniel R., Renner, Steffen, Honeder, Sophie E., Wu, Michelle, Chan, Sze Ham, Tseyang, Tenzin, Stoltzfus, Andrew T., Michel, Sarah L.J., Greaves, Daniel, Hsu, Peggy P., Ng, Christopher W., Zhang, Chelsea J., Farsidjani, Ali, Kent, Johnathan R., Madariaga, Maria Lucia L., Gramatikov, Iva Monique T., Matheson, Nicholas J., Lewis, Caroline A., Clish, Clary B., Rees, Matthew G., Roth, Jennifer A., Griner, Lesley Mathews, Muir, Alexander, Auld, Douglas S., and Vander Heiden, Matthew G.
Published: 2023
Full Text: View/download PDF

6. Proteomic analysis of circulating immune cells identifies cellular phenotypes associated with COVID-19 severity

Author: Potts, Martin, Fletcher-Etherington, Alice, Nightingale, Katie, Mescia, Federica, Bergamaschi, Laura, Calero-Nieto, Fernando J., Antrobus, Robin, Williamson, James, Parsons, Harriet, Huttlin, Edward L., Kingston, Nathalie, Göttgens, Berthold, Bradley, John R., Lehner, Paul J., Matheson, Nicholas J., Smith, Kenneth G.C., Wills, Mark R., Lyons, Paul A., and Weekes, Michael P.
Published: 2023
Full Text: View/download PDF

7. Attenuated humoral responses in HIV after SARS-CoV-2 vaccination linked to B cell defects and altered immune profiles

Author: Touizer, Emma, Alrubayyi, Aljawharah, Ford, Rosemarie, Hussain, Noshin, Gerber, Pehuén Pereyra, Shum, Hiu-Long, Rees-Spear, Chloe, Muir, Luke, Gea-Mallorquí, Ester, Kopycinski, Jakub, Jankovic, Dylan, Jeffery-Smith, Anna, Pinder, Christopher L., Fox, Thomas A., Williams, Ian, Mullender, Claire, Maan, Irfaan, Waters, Laura, Johnson, Margaret, Madge, Sara, Youle, Michael, Barber, Tristan J., Burns, Fiona, Kinloch, Sabine, Rowland-Jones, Sarah, Gilson, Richard, Matheson, Nicholas J., Morris, Emma, Peppa, Dimitra, and McCoy, Laura E.
Published: 2023
Full Text: View/download PDF

8. Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity

Author: Meng, Bo, Abdullahi, Adam, Ferreira, Isabella A. T. M., Goonawardane, Niluka, Saito, Akatsuki, Kimura, Izumi, Yamasoba, Daichi, Gerber, Pehuén Pereyra, Fatihi, Saman, Rathore, Surabhi, Zepeda, Samantha K., Papa, Guido, Kemp, Steven A., Ikeda, Terumasa, Toyoda, Mako, Tan, Toong Seng, Kuramochi, Jin, Mitsunaga, Shigeki, Ueno, Takamasa, Shirakawa, Kotaro, Takaori-Kondo, Akifumi, Brevini, Teresa, Mallery, Donna L., Charles, Oscar J., Bowen, John E., Joshi, Anshu, Walls, Alexandra C., Jackson, Laurelle, Martin, Darren, Smith, Kenneth G. C., Bradley, John, Briggs, John A. G., Choi, Jinwook, Madissoon, Elo, Meyer, Kerstin B., Mlcochova, Petra, Ceron-Gutierrez, Lourdes, Doffinger, Rainer, Teichmann, Sarah A., Fisher, Andrew J., Pizzuto, Matteo S., de Marco, Anna, Corti, Davide, Hosmillo, Myra, Lee, Joo Hyeon, James, Leo C., Thukral, Lipi, Veesler, David, Sigal, Alex, Sampaziotis, Fotios, Goodfellow, Ian G., Matheson, Nicholas J., Sato, Kei, and Gupta, Ravindra K.
Published: 2022
Full Text: View/download PDF

9. Genomic epidemiology of SARS-CoV-2 in a UK university identifies dynamics of transmission

Author: Aggarwal, Dinesh, Warne, Ben, Jahun, Aminu S., Hamilton, William L., Fieldman, Thomas, du Plessis, Louis, Hill, Verity, Blane, Beth, Watkins, Emmeline, Wright, Elizabeth, Hall, Grant, Ludden, Catherine, Myers, Richard, Hosmillo, Myra, Chaudhry, Yasmin, Pinckert, Malte L., Georgana, Iliana, Izuagbe, Rhys, Leek, Danielle, Nsonwu, Olisaeloka, Hughes, Gareth J., Packer, Simon, Page, Andrew J., Metaxaki, Marina, Fuller, Stewart, Weale, Gillian, Holgate, Jon, Brown, Christopher A., Howes, Rob, McFarlane, Duncan, Dougan, Gordon, Pybus, Oliver G., Angelis, Daniela De, Maxwell, Patrick H., Peacock, Sharon J., Weekes, Michael P., Illingworth, Chris, Harrison, Ewan M., Matheson, Nicholas J., and Goodfellow, Ian G.
Published: 2022
Full Text: View/download PDF

10. XNAzymes targeting the SARS-CoV-2 genome inhibit viral infection

Author: Gerber, Pehuén Pereyra, Donde, Maria J., Matheson, Nicholas J., and Taylor, Alexander I.
Published: 2022
Full Text: View/download PDF

11. Bioengineered small extracellular vesicles deliver multiple SARS‐CoV‐2 antigenic fragments and drive a broad immunological response

Author: Jackson, Hannah K., primary, Long, Heather M., additional, Yam‐Puc, Juan Carlos, additional, Palmulli, Roberta, additional, Haigh, Tracey A., additional, Gerber, Pehuén Pereyra, additional, Lee, Jin S., additional, Matheson, Nicholas J., additional, Young, Lesley, additional, Trowsdale, John, additional, Lo, Mathew, additional, Taylor, Graham S., additional, Thaventhiran, James E., additional, and Edgar, James R., additional
Published: 2024
Full Text: View/download PDF

12. Covid-19 : should the public wear face masks?

Author: Javid, Babak, Weekes, Michael P, and Matheson, Nicholas J
Published: 2020

13. Point of Care Nucleic Acid Testing for SARS-CoV-2 in Hospitalized Patients: A Clinical Validation Trial and Implementation Study

Author: Baker, Stephen, Bradley, John, Dougan, Gordon, Goodfellow, Ian, Gupta, Ravindra K., Lehner, Paul J., Lyons, Paul, Matheson, Nicholas J., Smith, Kenneth G.C., Toshner, Mark, Weekes, Michael P., Brown, Nick, Curran, Martin, Palmar, Surendra, Zhang, Hongyi, Enoch, David, Chapman, Daniel, Shaw, Ashley, Mendoza, Vivien, Jose, Sherly, Bermperi, Areti, Zerrudo, Julie Ann, Kourampa, Evgenia, Saunders, Caroline, de Jesus, Ranalie, Domingo, Jason, Pasquale, Ciro, Vergese, Bensi, Vargas, Phoebe, Fabiculana, Marivic, Perales, Marlyn, Skells, Richard, Mynott, Lee, Blake, Elizabeth, Bates, Amy, Vallier, Anne-laure, Williams, Alexandra, Phillips, David, Chiu, Edmund, Overhill, Alex, Ramenante, Nicola, Sipple, Jamal, Frost, Steven, Knock, Helena, Hardy, Richard, Foster, Emily, Davidson, Fiona, Rundell, Viona, Bundi, Purity, Abeseabe, Richmond, Clark, Sarah, Vicente, Isabel, Collier, Dami A., Assennato, Sonny M., Warne, Ben, Sithole, Nyarie, Sharrocks, Katherine, Ritchie, Allyson, Ravji, Pooja, Routledge, Matthew, Sparkes, Dominic, Skittrall, Jordan, Smielewska, Anna, Ramsey, Isobel, Goel, Neha, Tassell, Rhys, Lineham, Michelle, Vaghela, Devan, Leong, Clare, Mok, Hoi Ping, Mendoza, Vivienne, Demiris, Nikos, Besser, Martin, Siedner, Mark J., Waddington, Claire S., and Lee, Helen
Published: 2020
Full Text: View/download PDF

14. A Simulation Model and Dashboard for Predicting Covid-19 Bed Requirements

Author: Chan, Yin-Chi, primary, Dreesbeimdiek, Kaya, additional, Parlikad, Ajith Kumar, additional, Ridgman, Tom, additional, Matheson, Nicholas J., additional, Warne, Ben, additional, and Franks, Denise, additional
Published: 2023
Full Text: View/download PDF

15. Accelerated waning of the humoral response to COVID-19 vaccines in obesity

Author: van der Klaauw, Agatha A, Horner, Emily C, Pereyra-Gerber, Pehuén, Agrawal, Utkarsh, Foster, William S, Spencer, Sarah, Vergese, Bensi, Smith, Miriam, Henning, Elana, Ramsay, Isobel D, Smith, Jack A, Guillaume, Stephane M, Sharpe, Hayley J, Hay, Iain M, Thompson, Sam, Innocentin, Silvia, Booth, Lucy H, Robertson, Chris, McCowan, Colin, Kerr, Steven, Mulroney, Thomas E, O'Reilly, Martin J, Gurugama, Thevinya P, Gurugama, Lihinya P, Rust, Maria A, Ferreira, Alex, Ebrahimi, Soraya, Ceron-Gutierrez, Lourdes, Scotucci, Jacopo, Kronsteiner, Barbara, Dunachie, Susanna J, Klenerman, Paul, PITCH Consortium, Park, Adrian J, Rubino, Francesco, Lamikanra, Abigail A, Stark, Hannah, Kingston, Nathalie, Estcourt, Lise, Harvala, Heli, Roberts, David J, Doffinger, Rainer, Linterman, Michelle A, Matheson, Nicholas J, Sheikh, Aziz, Farooqi, I Sadaf, Thaventhiran, James ED, University of St Andrews. School of Medicine, University of St Andrews. Sir James Mackenzie Institute for Early Diagnosis, University of St Andrews. Population and Behavioural Science Division, van der Klaauw, Agatha A [0000-0001-6971-8828], Horner, Emily C [0000-0003-2226-1028], Agrawal, Utkarsh [0000-0001-5181-6120], Foster, William S [0000-0002-7103-3657], Ramsay, Isobel D [0000-0002-9954-2023], Smith, Jack A [0000-0001-6654-5706], Guillaume, Stephane M [0000-0003-2007-4608], Sharpe, Hayley J [0000-0002-4723-298X], Hay, Iain M [0000-0002-5451-1768], McCowan, Colin [0000-0002-9466-833X], O'Reilly, Martin J [0000-0003-1095-0328], Ferreira, Alex [0000-0002-1964-1049], Kronsteiner, Barbara [0000-0003-0867-2867], Dunachie, Susanna J [0000-0001-5665-6293], Klenerman, Paul [0000-0003-4307-9161], Park, Adrian J [0000-0003-2713-7595], Linterman, Michelle A [0000-0001-6047-1996], Matheson, Nicholas J [0000-0002-3318-1851], Sheikh, Aziz [0000-0001-7022-3056], Farooqi, I Sadaf [0000-0001-7609-3504], Thaventhiran, James ED [0000-0001-8616-074X], and Apollo - University of Cambridge Repository
Subjects: MCC, COVID-19 Vaccines, SARS-CoV-2, Vaccination, COVID-19, DAS, Antibodies, Viral, Antibodies, Neutralizing, Obesity, Morbid, SDG 3 - Good Health and Well-being, RA0421, RA0421 Public health. Hygiene. Preventive Medicine, Humans, Longitudinal Studies, Prospective Studies, Obesity
Abstract: Funding: EAVE II is funded by the Medical Research Council (MRC) (MC_PC_19075) with the support of BREATHE—The Health Data Research Hub for Respiratory Health (MC_PC_19004), which is funded through the UK Research and Innovation Industrial Strategy Challenge Fund and delivered through Health Data Research UK. This research is part of the Data and Connectivity National Core Study, led by Health Data Research UK in partnership with the Office for National Statistics and funded by UK Research and Innovation (grant MC_PC_20058) and National Core Studies–Immunity. Additional support was provided through Public Health Scotland, the Scottish Government Director-General Health and Social Care and the University of Edinburgh. The SCORPIO study was supported by the MRC (MR/W020564/1, a core award to J.E.T.; MC_UU_0025/12 and MR/T032413/1, awards to N.J.M.) and the Medical Research Foundation (MRF-057-0002-RG-THAV-C0798). Additional support was provided by NHS Blood and Transplant (WPA15-02 to N.J.M.), the Wellcome Trust (Institutional Strategic Support Fund 204845/Z/16/Z to N.J.M.), Addenbrooke’s Charitable Trust (900239 to N.J.M.) and the NIHR Cambridge Biomedical Research Centre and NIHR BioResource. M.A.L is supported by the Biotechnology and Biological Sciences Research Council (BBSRC) (BBS/E/B/000C0427 and BBS/E/B/000C0428) and is a Lister Institute Fellow and an EMBO Young Investigator. I.M.H. is supported by a Cambridge Institute for Medical Research PhD studentship. H.J.S. is supported by a Sir Henry Dale Fellowship, jointly funded by the Wellcome Trust and the Royal Society (109407), and a BBSRC institutional program grant (BBS/E/B/000C0433). I.S.F. is supported by the Wellcome Trust (207462/Z/17/Z), the Botnar Fondation, the Bernard Wolfe Health Neuroscience Endowment and an NIHR Senior Investigator Award. Obesity is associated with an increased risk of severe Coronavirus Disease 2019 (COVID-19) infection and mortality. COVID-19 vaccines reduce the risk of serious COVID-19 outcomes; however, their effectiveness in people with obesity is incompletely understood. We studied the relationship among body mass index (BMI), hospitalization and mortality due to COVID-19 among 3.6 million people in Scotland using the Early Pandemic Evaluation and Enhanced Surveillance of COVID-19 (EAVE II) surveillance platform. We found that vaccinated individuals with severe obesity (BMI > 40 kg/m2) were 76% more likely to experience hospitalization or death from COVID-19 (adjusted rate ratio of 1.76 (95% confidence interval (CI), 1.60–1.94). We also conducted a prospective longitudinal study of a cohort of 28 individuals with severe obesity compared to 41 control individuals with normal BMI (BMI 18.5–24.9 kg/m2). We found that 55% of individuals with severe obesity had unquantifiable titers of neutralizing antibody against authentic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus compared to 12% of individuals with normal BMI (P = 0.0003) 6 months after their second vaccine dose. Furthermore, we observed that, for individuals with severe obesity, at any given anti-spike and anti-receptor-binding domain (RBD) antibody level, neutralizing capacity was lower than that of individuals with a normal BMI. Neutralizing capacity was restored by a third dose of vaccine but again declined more rapidly in people with severe obesity. We demonstrate that waning of COVID-19 vaccine-induced humoral immunity is accelerated in individuals with severe obesity. As obesity is associated with increased hospitalization and mortality from breakthrough infections, our findings have implications for vaccine prioritization policies. Publisher PDF
Published: 2023

16. A histone deacetylase 3 and mitochondrial complex I axis regulates toxic formaldehyde production

Author: Wit, Niek, primary, Gogola, Ewa, additional, West, James A., additional, Vornbäumen, Tristan, additional, Seear, Rachel V., additional, Bailey, Peter S. J., additional, Burgos-Barragan, Guillermo, additional, Wang, Meng, additional, Krawczyk, Patrycja, additional, Huberts, Daphne H. E. W., additional, Gergely, Fanni, additional, Matheson, Nicholas J., additional, Kaser, Arthur, additional, Nathan, James A., additional, and Patel, Ketan J., additional
Published: 2023
Full Text: View/download PDF

17. Integrative functional genomics decodes herpes simplex virus 1

Author: Whisnant, Adam W., Jürges, Christopher S., Hennig, Thomas, Wyler, Emanuel, Prusty, Bhupesh, Rutkowski, Andrzej J., L’hernault, Anne, Djakovic, Lara, Göbel, Margarete, Döring, Kristina, Menegatti, Jennifer, Antrobus, Robin, Matheson, Nicholas J., Künzig, Florian W. H., Mastrobuoni, Guido, Bielow, Chris, Kempa, Stefan, Liang, Chunguang, Dandekar, Thomas, Zimmer, Ralf, Landthaler, Markus, Grässer, Friedrich, Lehner, Paul J., Friedel, Caroline C., Erhard, Florian, and Dölken, Lars
Published: 2020
Full Text: View/download PDF

18. FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2

Author: Brevini, Teresa, Maes, Mailis, Webb, Gwilym J, John, Binu V, Fuchs, Claudia D, Buescher, Gustav, Wang, Lu, Griffiths, Chelsea, Brown, Marnie L, Scott, William E, Pereyra-Gerber, Pehuén, Gelson, William TH, Brown, Stephanie, Dillon, Scott, Muraro, Daniele, Sharp, Jo, Neary, Megan, Box, Helen, Tatham, Lee, Stewart, James, Curley, Paul, Pertinez, Henry, Forrest, Sally, Mlcochova, Petra, Varankar, Sagar S, Darvish-Damavandi, Mahnaz, Mulcahy, Victoria L, Kuc, Rhoda E, Williams, Thomas L, Heslop, James A, Rossetti, Davide, Tysoe, Olivia C, Galanakis, Vasileios, Vila-Gonzalez, Marta, Crozier, Thomas WM, Bargehr, Johannes, Sinha, Sanjay, Upponi, Sara S, Fear, Corrina, Swift, Lisa, Saeb-Parsy, Kourosh, Davies, Susan E, Wester, Axel, Hagström, Hannes, Melum, Espen, Clements, Darran, Humphreys, Peter, Herriott, Jo, Kijak, Edyta, Cox, Helen, Bramwell, Chloe, Valentijn, Anthony, Illingworth, Christopher, UK-PBC Consortium, Dahman, Bassam, Bastaich, Dustin R, Ferreira, Raphaella D, Marjot, Thomas, Barnes, Eleanor, Moon, Andrew M, Barritt, Alfred S, Gupta, Ravindra K, Baker, Stephen, Davenport, Anthony P, Corbett, Gareth, Gorgoulis, Vassilis G, Buczacki, Simon JA, Lee, Joo-Hyeon, Matheson, Nicholas J, Trauner, Michael, Fisher, Andrew J, Gibbs, Paul, Butler, Andrew J, Watson, Christopher JE, Mells, George F, Dougan, Gordon, Owen, Andrew, Lohse, Ansgar W, Vallier, Ludovic, Sampaziotis, Fotios, Brevini, Teresa [0000-0002-3581-5379], Maes, Mailis [0000-0002-0266-6557], Wang, Lu [0000-0002-4418-8602], Brown, Marnie L [0000-0001-6463-0288], Scott, William E [0000-0003-1515-0514], Sharp, Jo [0000-0001-8482-5736], Neary, Megan [0000-0002-4960-2139], Tatham, Lee [0000-0001-9448-8876], Stewart, James [0000-0002-8928-2037], Darvish-Damavandi, Mahnaz [0000-0003-0226-2621], Williams, Thomas L [0000-0002-1051-0595], Crozier, Thomas WM [0000-0003-0951-4588], Bargehr, Johannes [0000-0002-9304-3573], Sinha, Sanjay [0000-0001-5900-1209], Saeb-Parsy, Kourosh [0000-0002-0633-3696], Wester, Axel [0000-0003-3634-6591], Melum, Espen [0000-0001-6903-6878], Bramwell, Chloe [0000-0001-8274-457X], Barnes, Eleanor [0000-0002-0860-0831], Moon, Andrew M [0000-0001-7163-2062], Gupta, Ravindra K [0000-0001-9751-1808], Baker, Stephen [0000-0003-1308-5755], Davenport, Anthony P [0000-0002-2096-3117], Gorgoulis, Vassilis G [0000-0001-9001-4112], Buczacki, Simon JA [0000-0002-2975-416X], Lee, Joo-Hyeon [0000-0002-7364-6422], Matheson, Nicholas J [0000-0002-3318-1851], Trauner, Michael [0000-0002-1275-6425], Fisher, Andrew J [0000-0003-4822-7223], Watson, Christopher JE [0000-0002-0590-4901], Owen, Andrew [0000-0002-9819-7651], Vallier, Ludovic [0000-0002-3848-2602], Sampaziotis, Fotios [0000-0003-0812-7586], and Apollo - University of Cambridge Repository
Subjects: Transcription, Genetic, SARS-CoV-2, Ursodeoxycholic Acid, COVID-19, Reproducibility of Results, COVID-19 Drug Treatment, Liver Transplantation, Organoids, Mice, Nasal Mucosa, Liver, Cricetinae, UK-PBC Consortium, Animals, Humans, Receptors, Virus, Angiotensin-Converting Enzyme 2, Registries, Lung, Retrospective Studies
Abstract: Acknowledgements: We thank the European Association for the Study of the Liver (EASL) and the American Association for the Study of Liver Disease (AASLD) for supporting the COVID-Hep and SECURE-Liver registries; S. Marciniak and P. J. Lehner for comments and feedback on the manuscript; I. Goodfellow for providing the viral isolate; M. Wills and S. Clare for all their work ensuring a safe CL-3 working environment; C. Cormie for general lab support; the NIHR Cambridge BRC Cell Phenotyping Hub for their help with flow cytometry and processing of samples; the building staff of the Jeffrey Cheah Biomedical Centre for maintaining the institute open and safe during the period of lockdown; K. Füssel for coordinating the volunteer study and sample collection at the University Medical Centre Hamburg-Eppendorf; J. Hails, K.-I. Nikitopoulou and A. Ford for collecting blood samples; M. Colzani for advising on flow cytometry; A. Wiblin for advising on antibodies; and the Cambridge Biorepository for Translational Medicine for the provision of human tissue used in the study. T.B. was supported by an EASL Juan Rodès PhD fellowship. F.S. was supported by a UKRI Future Leaders fellowship, the Evelyn trust, an NIHR Clinical Lectureship, the Academy of Medical Sciences Starter Grant for Clinical Lecturers, the Addenbrooke’s Charitable Trust and the Rosetrees Trust. In addition, the F.S. laboratory is supported by the Cambridge University Hospitals National Institute for Health Research Biomedical Research Centre and the core support grant from the Wellcome Trust and Medical Research Council (MRC) of the Wellcome–Medical Research Council Cambridge Stem Cell Institute. The L.V. laboratory is funded by the ERC advanced grant New-Chol, the Cambridge University Hospitals National Institute for Health Research Biomedical Research Centre and the core support grant from the Wellcome Trust and MRC of the Wellcome–Medical Research Council Cambridge Stem Cell Institute. M.M., S.F. and G.D. are funded by the NIHR Cambridge Biomedical Research Centre and NIHR AMR Research Capital Funding Scheme (NIHR200640). The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. V.L.M. was funded by an MRC Clinical Research Training Fellowship. G.F.M. was funded by a post-doctoral fellowship from the National Institute for Health Research (NIHR) Rare Diseases–Translational Research Collaboration (RD-TRC) and by an MRC Clinical Academic Research Partnership (CARP) award. The UK-PBC Nested Cohort study was funded by an MRC Stratified Medicine award (MR/L001489/1). C.J.R.I. was supported by the Medical Research Council (MC_UU_12014). T.M. is funded by a Wellcome Trust Clinical Research Training Fellowship (102176/B/13/Z). The A.P.D. laboratory was supported by BHF TG/18/4/33770, Wellcome Trust 203814/Z/16/A and Addenbrooke’s Charitable Trust. The COVID-Hep.net registry was supported by the European Association for the Study of the Liver (EASL) and the SECURE-Liver registry was supported by the American Association for the Study of Liver Disease (AASLD). The lung perfusion experiment was supported by the National Institute for Health Research Blood and Transplant Research Unit (NIHR BTRU) in Organ Donation and Transplantation at Newcastle University and the University of Cambridge in partnership with NHS Blood and Transplant (NHSBT). The views expressed are those of the author(s) and not necessarily those of the NIHR, the Department of Health and Social Care or NHSBT. G.B. is funded by the European Reference Network for Hepatological Diseases (ERN RARE LIVER). A.O. acknowledges funding for preclinical research on treatment and prevention of COVID-19 from Unitaid (2020-38-LONGEVITY), the Engineering and Physical Sciences Research Council (EPSRC; EP/R024804/1), the Wellcome Trust (222489/Z/21/Z) and UK Research and Innovation (UKRI; BB/W010801/1). N.J.M. acknowledges funding from the MRC (CSF ref. MR/P008801/1 to N.J.M.), NHSBT (grant ref. WPA15-02 to N.J.M.) and Addenbrooke’s Charitable Trust (grant ref. to 900239 N.J.M.). This research was funded in whole, or in part, by the Wellcome Trust (203151/Z/16/Z, 203151/A/16/Z) and the UKRI Medical Research Council (MC_PC_17230). For the purpose of open access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission., Preventing SARS-CoV-2 infection by modulating viral host receptors, such as angiotensin-converting enzyme 2 (ACE2)1, could represent a new chemoprophylactic approach for COVID-19 that complements vaccination2,3. However, the mechanisms that control the expression of ACE2 remain unclear. Here we show that the farnesoid X receptor (FXR) is a direct regulator of ACE2 transcription in several tissues affected by COVID-19, including the gastrointestinal and respiratory systems. We then use the over-the-counter compound z-guggulsterone and the off-patent drug ursodeoxycholic acid (UDCA) to reduce FXR signalling and downregulate ACE2 in human lung, cholangiocyte and intestinal organoids and in the corresponding tissues in mice and hamsters. We show that the UDCA-mediated downregulation of ACE2 reduces susceptibility to SARS-CoV-2 infection in vitro, in vivo and in human lungs and livers perfused ex situ. Furthermore, we reveal that UDCA reduces the expression of ACE2 in the nasal epithelium in humans. Finally, we identify a correlation between UDCA treatment and positive clinical outcomes after SARS-CoV-2 infection using retrospective registry data, and confirm these findings in an independent validation cohort of recipients of liver transplants. In conclusion, we show that FXR has a role in controlling ACE2 expression and provide evidence that modulation of this pathway could be beneficial for reducing SARS-CoV-2 infection, paving the way for future clinical trials.
Published: 2022

19. Screening in serum-derived medium reveals differential response to compounds targeting metabolism

Author: Abbott, Keene L., primary, Ali, Ahmed, additional, Casalena, Dominick, additional, Do, Brian T., additional, Ferreira, Raphael, additional, Cheah, Jaime H., additional, Soule, Christian K., additional, Deik, Amy, additional, Kunchok, Tenzin, additional, Schmidt, Daniel R., additional, Renner, Steffen, additional, Honeder, Sophie E., additional, Wu, Michelle, additional, Chan, Sze Ham, additional, Tseyang, Tenzin, additional, Greaves, Daniel, additional, Hsu, Peggy P., additional, Ng, Christopher W., additional, Zhang, Chelsea J., additional, Farsidjani, Ali, additional, Gramatikov, Iva Monique T., additional, Matheson, Nicholas J., additional, Lewis, Caroline A., additional, Clish, Clary B., additional, Rees, Matthew G., additional, Roth, Jennifer A., additional, Griner, Lesley Mathews, additional, Muir, Alexander, additional, Auld, Douglas S., additional, and Heiden, Matthew G. Vander, additional
Published: 2023
Full Text: View/download PDF

20. LRRC15 mediates an accessory interaction with the SARS-CoV-2 spike protein

Author: Shilts, Jarrod, primary, Crozier, Thomas W. M., additional, Teixeira-Silva, Ana, additional, Gabaev, Ildar, additional, Gerber, Pehuén Pereyra, additional, Greenwood, Edward J. D., additional, Watson, Samuel James, additional, Ortmann, Brian M., additional, Gawden-Bone, Christian M., additional, Pauzaite, Tekle, additional, Hoffmann, Markus, additional, Nathan, James A., additional, Pöhlmann, Stefan, additional, Matheson, Nicholas J., additional, Lehner, Paul J., additional, and Wright, Gavin J., additional
Published: 2023
Full Text: View/download PDF

21. Microfluidics-enabled fluorescence-activated cell sorting of single pathogen-specific antibody secreting cells for the rapid discovery of monoclonal antibodies

Author: Fischer, Katrin, primary, Lulla, Aleksei, additional, So, Tsz Y, additional, Pereyra-Gerber, Pehuén, additional, Raybould, Matthew I. J., additional, Kohler, Timo N., additional, Kaminski, Tomasz S., additional, Yam-Puc, Juan Carlos, additional, Hughes, Robert, additional, Leiß-Maier, Florian, additional, Brear, Paul, additional, Matheson, Nicholas J., additional, Deane, Charlotte M., additional, Hyvönen, Marko, additional, Thaventhiran, James E. D., additional, and Hollfelder, Florian, additional
Published: 2023
Full Text: View/download PDF

22. Multiomic Analysis Identifies Metabolic Enhancement of Immune Memory by Increased Glutaminolysis in Cells, Mice and Humans

Author: Sowerby, John M., primary, Kotagiri, Prasanti, additional, Clare, Simon, additional, Griffiths, Daniel, additional, Knight, Oliver, additional, Cuthbertson, Iona, additional, Harcourt, Katherine, additional, Pereyra Gerber, Federico Pehuen, additional, Pshenichnaya, Irina, additional, Connor, Chris, additional, Denton, Alice E., additional, Stoll, Guido, additional, Matara, Cecilia, additional, Keel, Carol, additional, Manferrari, Giulia, additional, Birkle, Tim, additional, Naydenova, Plamena, additional, Peck, Heidi, additional, Lyons, Paul A., additional, Barr, Ian, additional, Modis, Yorgo, additional, Dougan, Gordon, additional, Matheson, Nicholas J., additional, Smith, KGC, additional, and McKinney, Eoin, additional
Published: 2023
Full Text: View/download PDF

23. LRRC15 mediates an accessory interaction with the SARS-CoV-2 spike protein

Author: Shilts, Jarrod, Crozier, Thomas WM, Teixeira-Silva, Ana, Gabaev, Ildar, Gerber, Pehuén Pereyra, Greenwood, Edward JD, Watson, Samuel James, Ortmann, Brian M, Gawden-Bone, Christian M, Pauzaite, Tekle, Hoffmann, Markus, Nathan, James A, Pöhlmann, Stefan, Matheson, Nicholas J, Lehner, Paul J, Wright, Gavin J, Shilts, Jarrod [0000-0002-0959-0583], Crozier, Thomas WM [0000-0003-0951-4588], Teixeira-Silva, Ana [0000-0002-9011-9501], Greenwood, Edward JD [0000-0002-5224-0263], Gawden-Bone, Christian M [0000-0003-0413-3727], Pauzaite, Tekle [0000-0002-0668-3661], Hoffmann, Markus [0000-0003-4603-7696], Nathan, James A [0000-0002-0248-1632], Pöhlmann, Stefan [0000-0001-6086-9136], Lehner, Paul J [0000-0001-9383-1054], Wright, Gavin J [0000-0003-0537-0863], and Apollo - University of Cambridge Repository
Subjects: General Immunology and Microbiology, SARS-CoV-2, General Neuroscience, Spike Glycoprotein, Coronavirus, Humans, COVID-19, Membrane Proteins, Angiotensin-Converting Enzyme 2, General Agricultural and Biological Sciences, General Biochemistry, Genetics and Molecular Biology, Protein Binding
Abstract: Acknowledgements: An RPE-1 cell line expressing dCas9-SunTag10x_v4-P2A-mCherry and scFv-GCN4-GFP-VP64 was provided by Marvin Tanenbaum and Jonathan Weissman. pCCI-4K-SARS-CoV-2-ZsGreen was a gift from Sam Wilson, University of Glasgow. The viral isolate SARS-CoV-2/human/Liverpool/REMRQ0001/2020 was a gift from Ian Goodfellow, University of Cambridge. FACS experiments were enabled by Dr. Anna Petrunkina Harrison, and Arrayscan experiments were enabled by Veronika Romashova at the JCBC FACS core facilities. Thanks to Liane Dupont and Zheng-Shan Chong for useful advice on the design of CRISPRa screens., Funder: Addenbrooke’s Charitable Trust, Cambridge University Hospitals; funder-id: http://dx.doi.org/10.13039/501100002927, Funder: NIHR Cambridge Biomedical Research Centre; funder-id: http://dx.doi.org/10.13039/501100018956, Funder: NIHR Cambridge Biomedical Research Centre, The interactions between Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and human host factors enable the virus to propagate infections that lead to Coronavirus Disease 2019 (COVID-19). The spike protein is the largest structural component of the virus and mediates interactions essential for infection, including with the primary angiotensin-converting enzyme 2 (ACE2) receptor. We performed two independent cell-based systematic screens to determine whether there are additional proteins by which the spike protein of SARS-CoV-2 can interact with human cells. We discovered that in addition to ACE2, expression of LRRC15 also causes spike protein binding. This interaction is distinct from other known spike attachment mechanisms such as heparan sulfates or lectin receptors. Measurements of orthologous coronavirus spike proteins implied the interaction was functionally restricted to SARS-CoV-2 by accessibility. We localized the interaction to the C-terminus of the S1 domain and showed that LRRC15 shares recognition of the ACE2 receptor binding domain. From analyzing proteomics and single-cell transcriptomics, we identify LRRC15 expression as being common in human lung vasculature cells and fibroblasts. Levels of LRRC15 were greatly elevated by inflammatory signals in the lungs of COVID-19 patients. Although infection assays demonstrated that LRRC15 alone is not sufficient to permit viral entry, we present evidence that it can modulate infection of human cells. This unexpected interaction merits further investigation to determine how SARS-CoV-2 exploits host LRRC15 and whether it could account for any of the distinctive features of COVID-19.
Published: 2023

24. Attenuated humoral responses in HIV infection after SARS-CoV-2 vaccination are linked to global B cell defects and cellular immune profiles

Author: Touizer, Emma, primary, Alrubbayi, Aljawharah, additional, Ford, Rosemarie, additional, Hussain, Noshin, additional, Gerber, Pehuén Pereyra, additional, Shum, Hiu-Long, additional, Rees-Spear, Chloe, additional, Muir, Luke, additional, Gea-Mallorquí, Ester, additional, Kopycinski, Jakub, additional, Jankovic, Dylan, additional, Pinder, Christopher, additional, Fox, Thomas A, additional, Williams, Ian, additional, Mullender, Claire, additional, Maan, Irfaan, additional, Waters, Laura, additional, Johnson, Margaret, additional, Madge, Sara, additional, Youle, Michael, additional, Barber, Tristan, additional, Burns, Fiona, additional, Kinloch, Sabine, additional, Rowland-Jones, Sarah, additional, Gilson, Richard, additional, Matheson, Nicholas J, additional, Morris, Emma, additional, Peppa, Dimitra, additional, and McCoy, Laura E, additional
Published: 2022
Full Text: View/download PDF

25. Epigenetic silencing by the HUSH complex mediates position-effect variegation in human cells

Author: Tchasovnikarova, Iva A., Timms, Richard T., Matheson, Nicholas J., Wals, Kim, Antrobus, Robin, Göttgens, Berthold, Dougan, Gordon, Dawson, Mark A., and Lehner, Paul J.
Published: 2015

26. Evidence of previous SARS-CoV-2 infection in seronegative patients with long COVID

Author: Krishna, Benjamin A, Lim, Eleanor Y, Mactavous, Lenette, NIHR BioResource Team, Lyons, Paul A, Doffinger, Rainer, Bradley, John R, Smith, Kenneth GC, Sinclair, John, Matheson, Nicholas J, Lehner, Paul J, Wills, Mark R, Sithole, Nyaradzai, Krishna, Benjamin Anthony Cates [0000-0003-0919-2961], Bradley, John [0000-0002-7774-8805], Smith, Kenneth [0000-0003-3829-4326], Sinclair, John [0000-0002-2616-9571], Wills, Mark [0000-0001-8548-5729], Sithole, Nyarie [0000-0002-8020-223X], and Apollo - University of Cambridge Repository
Subjects: Long COVID, Post-Acute COVID-19 Syndrome, SARS-CoV-2, Immunity, Assay, T cell, COVID-19, Humans, Interleukin-2, Antibodies, Viral
Abstract: BACKGROUND: There is currently no consensus on the diagnosis, definition, symptoms, or duration of COVID-19 illness. The diagnostic complexity of Long COVID is compounded in many patients who were or might have been infected with SARS-CoV-2 but not tested during the acute illness and/or are SARS-CoV-2 antibody negative. METHODS: Given the diagnostic conundrum of Long COVID, we set out to investigate SARS-CoV-2-specific T cell responses in patients with confirmed SARS-CoV-2 infection and/or Long COVID from a cohort of mostly non-hospitalised patients. FINDINGS: We discovered that IL-2 release (but not IFN-γ release) from T cells in response to SARS-CoV-2 peptides is both sensitive (75% +/-13%) and specific (88%+/-7%) for previous SARS-CoV-2 infection >6 months after a positive PCR test. We identified that 42-53% of patients with Long COVID, but without detectable SARS-CoV-2 antibodies, nonetheless have detectable SARS-CoV-2 specific T cell responses. INTERPRETATION: Our study reveals evidence (detectable T cell mediated IL-2 release) of previous SARS-CoV-2 infection in seronegative patients with Long COVID. FUNDING: This work was funded by the Addenbrooke's Charitable Trust (900276 to NS), NIHR award (G112259 to NS) and supported by the NIHR Cambridge Biomedical Research Centre. NJM is supported by the MRC (TSF MR/T032413/1) and NHSBT (WPA15-02). PJL is supported by the Wellcome Trust (PRF 210688/Z/18/Z, 084957/Z/08/Z), a Medical Research Council research grant MR/V011561/1 and the United Kingdom Research and a Innovation COVID Immunology Consortium grant (MR/V028448/1).
Published: 2022
Full Text: View/download PDF

27. Spontaneous, persistent T-cell dependent IFN-γ release in patients who progress to Long COVID

Author: Krishna, Benjamin A., primary, Lim, Eleanor Y., additional, Mactavous, Lenette, additional, Jackson, Sarah, additional, Team, NIHR BioResource, additional, Lyons, Paul A., additional, Doffinger, Rainer, additional, Bradley, John R., additional, Smith, Kenneth G. C., additional, Sinclair, John, additional, Matheson, Nicholas J., additional, Lehner, Paul J., additional, Sithole, Nyaradzai, additional, and Wills, Mark R., additional
Published: 2022
Full Text: View/download PDF

28. Quantitative proteomic analysis of SARS-CoV-2 infection of primary human airway ciliated cells and lung epithelial cells demonstrates the effectiveness of SARS-CoV-2 innate immune evasion

Author: Crozier, Thomas W.M., primary, Greenwood, Edward J.D., additional, Williamson, James C., additional, Guo, Wenrui, additional, Porter, Linsey M., additional, Gabaev, Ildar, additional, Teixeira-Silva, Ana, additional, Grice, Guinevere L., additional, Wickenhagen, Arthur, additional, Stanton, Richard J., additional, Wang, Eddie C. Y., additional, Wilson, Sam J., additional, Matheson, Nicholas J., additional, Nathan, James A., additional, McCaughan, Frank, additional, and Lehner, Paul J., additional
Published: 2022
Full Text: View/download PDF

29. SARS-CoV-2 spike N-terminal domain modulates TMPRSS2-dependent viral entry and fusogenicity

Author: Meng, Bo, primary, Datir, Rawlings, additional, Choi, Jinwook, additional, Bradley, John R., additional, Smith, Kenneth G.C., additional, Lee, Joo Hyeon, additional, Gupta, Ravindra K., additional, Baker, Stephen, additional, Dougan, Gordon, additional, Hess, Christoph, additional, Kingston, Nathalie, additional, Lehner, Paul J., additional, Lyons, Paul A., additional, Matheson, Nicholas J., additional, Owehand, Willem H., additional, Saunders, Caroline, additional, Summers, Charlotte, additional, Thaventhiran, James E.D., additional, Toshner, Mark, additional, Weekes, Michael P., additional, Maxwell, Patrick, additional, Shaw, Ashley, additional, Bucke, Ashlea, additional, Calder, Jo, additional, Canna, Laura, additional, Domingo, Jason, additional, Elmer, Anne, additional, Fuller, Stewart, additional, Harris, Julie, additional, Hewitt, Sarah, additional, Kennet, Jane, additional, Jose, Sherly, additional, Kourampa, Jenny, additional, Meadows, Anne, additional, O’Brien, Criona, additional, Price, Jane, additional, Publico, Cherry, additional, Rastall, Rebecca, additional, Ribeiro, Carla, additional, Rowlands, Jane, additional, Ruffolo, Valentina, additional, Tordesillas, Hugo, additional, Bullman, Ben, additional, Dunmore, Benjamin J., additional, Fawke, Stuart, additional, Gräf, Stefan, additional, Hodgson, Josh, additional, Huang, Christopher, additional, Hunter, Kelvin, additional, Jones, Emma, additional, Legchenko, Ekaterina, additional, Matara, Cecilia, additional, Martin, Jennifer, additional, Mescia, Federica, additional, O’Donnell, Ciara, additional, Pointon, Linda, additional, Shih, Joy, additional, Sutcliffe, Rachel, additional, Tilly, Tobias, additional, Treacy, Carmen, additional, Tong, Zhen, additional, Wood, Jennifer, additional, Wylot, Marta, additional, Betancourt, Ariana, additional, Bower, Georgie, additional, Cossetti, Chiara, additional, De Sa, Aloka, additional, Epping, Madeline, additional, Gleadall, Nick, additional, Grenfell, Richard, additional, Hinch, Andrew, additional, Jackson, Sarah, additional, Jarvis, Isobel, additional, Krishna, Ben, additional, Nice, Francesca, additional, Omarjee, Ommar, additional, Perera, Marianne, additional, Potts, Martin, additional, Richoz, Nathan, additional, Romashova, Veronika, additional, Stefanucci, Luca, additional, Strezlecki, Mateusz, additional, Turner, Lori, additional, De Bie, Eckart M.D.D., additional, Bunclark, Katherine, additional, Josipovic, Masa, additional, Mackay, Michael, additional, Allison, John, additional, Butcher, Helen, additional, Caputo, Daniela, additional, Clapham-Riley, Debbie, additional, Dewhurst, Eleanor, additional, Furlong, Anita, additional, Graves, Barbara, additional, Gray, Jennifer, additional, Ivers, Tasmin, additional, Le Gresley, Emma, additional, Linger, Rachel, additional, Meloy, Sarah, additional, Muldoon, Francesca, additional, Ovington, Nigel, additional, Papadia, Sofia, additional, Phelan, Isabel, additional, Stark, Hannah, additional, Stirrups, Kathleen E., additional, Townsend, Paul, additional, Walker, Neil, additional, Webster, Jennifer, additional, Scholtes, Ingrid, additional, Hein, Sabine, additional, and King, Rebecca, additional
Published: 2022
Full Text: View/download PDF

30. Evidence of previous SARS-CoV-2 infection in seronegative patients with long COVID

Author: Krishna, Benjamin A., primary, Lim, Eleanor Y., additional, Mactavous, Lenette, additional, Lyons, Paul A., additional, Doffinger, Rainer, additional, Bradley, John R., additional, Smith, Kenneth G.C., additional, Sinclair, John, additional, Matheson, Nicholas J., additional, Lehner, Paul J., additional, Wills, Mark R., additional, and Sithole, Nyaradzai, additional
Published: 2022
Full Text: View/download PDF

31. SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion

Author: Mlcochova, Petra, Kemp, Steven A., Dhar, Mahesh Shanker, Papa, Guido, Meng, Bo, Ferreira, Isabella A. T. M., Datir, Rawlings, Collier, Dami A., Albecka, Anna, Singh, Sujeet, Pandey, Rajesh, Brown, Jonathan, Zhou, Jie, Goonawardane, Niluka, Mishra, Swapnil, Whittaker, Charles, Mellan, Thomas, Marwal, Robin, Datta, Meena, Sengupta, Shantanu, Ponnusamy, Kalaiarasan, Radhakrishnan, Venkatraman Srinivasan, Abdullahi, Adam, Charles, Oscar, Chattopadhyay, Partha, Devi, Priti, Caputo, Daniela, Peacock, Tom, Wattal, Chand, Goel, Neeraj, Satwik, Ambrish, Vaishya, Raju, Agarwal, Meenakshi, Chauhan, Himanshu, Dikid, Tanzin, Gogia, Hema, Lall, Hemlata, Verma, Kaptan, Singh, Manoj K., Soni, Namita, Meena, Namonarayan, Madan, Preeti, Singh, Priyanka, Sharma, Ramesh, Sharma, Rajeev, Kabra, Sandhya, Kumar, Sattender, Kumari, Swati, Sharma, Uma, Chaudhary, Urmila, Sivasubbu, Sridhar, Scaria, Vinod, Oberoi, J. K., Raveendran, Reena, Datta, S., Das, Saumitra, Maitra, Arindam, Chinnaswamy, Sreedhar, Biswas, Nidhan Kumar, Parida, Ajay, Raghav, Sunil K., Prasad, Punit, Sarin, Apurva, Mayor, Satyajit, Ramakrishnan, Uma, Palakodeti, Dasaradhi, Seshasayee, Aswin Sai Narain, Thangaraj, K., Bashyam, Murali Dharan, Dalal, Ashwin, Bhat, Manoj, Shouche, Yogesh, Pillai, Ajay, Abraham, Priya, Potdar, Varsha Atul, Cherian, Sarah S., Desai, Anita Sudhir, Pattabiraman, Chitra, Manjunatha, M. V., Mani, Reeta S., Udupi, Gautam Arunachal, Nandicoori, Vinay, Tallapaka, Karthik Bharadwaj, Sowpati, Divya Tej, Kawabata, Ryoko, Morizako, Nanami, Sadamasu, Kenji, Asakura, Hiroyuki, Nagashima, Mami, Yoshimura, Kazuhisa, Ito, Jumpei, Kimura, Izumi, Uriu, Keiya, Kosugi, Yusuke, Suganami, Mai, Oide, Akiko, Yokoyama, Miyabishara, Chiba, Mika, Saito, Akatsuki, Butlertanaka, Erika P., Tanaka, Yuri L., Ikeda, Terumasa, Motozono, Chihiro, Nasser, Hesham, Shimizu, Ryo, Yuan, Yue, Kitazato, Kazuko, Hasebe, Haruyo, Nakagawa, So, Wu, Jiaqi, Takahashi, Miyoko, Fukuhara, Takasuke, Shimizu, Kenta, Tsushima, Kana, Kubo, Haruko, Shirakawa, Kotaro, Kazuma, Yasuhiro, Nomura, Ryosuke, Horisawa, Yoshihito, Takaori-Kondo, Akifumi, Tokunaga, Kenzo, Ozono, Seiya, Baker, Stephen, Dougan, Gordon, Hess, Christoph, Kingston, Nathalie, Lehner, Paul J., Lyons, Paul A., Matheson, Nicholas J., Owehand, Willem H., Saunders, Caroline, Summers, Charlotte, Thaventhiran, James E. D., Toshner, Mark, Weekes, Michael P., Maxwell, Patrick, Shaw, Ashley, Bucke, Ashlea, Calder, Jo, Canna, Laura, Domingo, Jason, Elmer, Anne, Fuller, Stewart, Harris, Julie, Hewitt, Sarah, Kennet, Jane, Jose, Sherly, Kourampa, Jenny, Meadows, Anne, O'Brien, Criona, Price, Jane, Publico, Cherry, Rastall, Rebecca, Ribeiro, Carla, Rowlands, Jane, Ruffolo, Valentina, Tordesillas, Hugo, Bullman, Ben, Dunmore, Benjamin J., Fawke, Stuart, Graf, Stefan, Hodgson, Josh, Huang, Christopher, Hunter, Kelvin, Jones, Emma, Legchenko, Ekaterina, Matara, Cecilia, Martin, Jennifer, Mescia, Federica, O'Donnell, Ciara, Pointon, Linda, Pond, Nicole, Shih, Joy, Sutcliffe, Rachel, Tilly, Tobias, Treacy, Carmen, Tong, Zhen, Wood, Jennifer, Wylot, Marta, Bergamaschi, Laura, Betancourt, Ariana, Bower, Georgie, Cossetti, Chiara, De Sa, Aloka, Epping, Madeline, Gleadall, Nick, Grenfell, Richard, Hinch, Andrew, Huhn, Oisin, Jackson, Sarah, Jarvis, Isobel, Krishna, Ben, Lewis, Daniel, Marsden, Joe, Nice, Francesca, Okecha, Georgina, Omarjee, Ommar, Perera, Marianne, Potts, Martin, Richoz, Nathan, Romashova, Veronika, Yarkoni, Natalia Savinykh, Sharma, Rahul, Stefanucci, Luca, Stephens, Jonathan, Strezlecki, Mateusz, Turner, Lori, De Bie, Eckart M. D. D., Bunclark, Katherine, Josipovic, Masa, Mackay, Michael, Rossi, Sabrina, Selvan, Mayurun, Spencer, Sarah, Yong, Cissy, Allison, John, Butcher, Helen, Clapham-Riley, Debbie, Dewhurst, Eleanor, Furlong, Anita, Graves, Barbara, Gray, Jennifer, Ivers, Tasmin, Kasanicki, Mary, Le Gresley, Emma, Linger, Rachel, Meloy, Sarah, Muldoon, Francesca, Ovington, Nigel, Papadia, Sofia, Phelan, Isabel, Stark, Hannah, Stirrups, Kathleen E., Townsend, Paul, Walker, Neil, Webster, Jennifer, Scholtes, Ingrid, Hein, Sabine, King, Rebecca, Mavousian, Antranik, Lee, Joo Hyeon, Bassi, Jessica, Silacci-Fegni, Chiara, Saliba, Christian, Pinto, Dora, Irie, Takashi, Yoshida, Isao, Hamilton, William L., Sato, Kei, Bhatt, Samir, Flaxman, Seth, James, Leo C., Corti, Davide, Piccoli, Luca, Barclay, Wendy S., Rakshit, Partha, Agrawal, Anurag, Gupta, Ravindra K., (INSACOG), Indian SARS-CoV-2 Genomics Consortium, Consortium, Genotype to Phenotype Japan (G2P-Japan), Collaboration, CITIID-NIHR BioResource COVID-19, Gupta, Ravindra K [0000-0001-9751-1808], Apollo - University of Cambridge Repository, and Gupta, Ravindra K. [0000-0001-9751-1808]
Subjects: Male, COVID-19 Vaccines, medicine.drug_class, Health Personnel, India, Monoclonal antibody, Virus Replication, Antibodies, Cell Line, Cell Fusion, Immune system, 13/100, medicine, Humans, Neutralizing antibody, Antibodies, Neutralizing, Female, Kinetics, SARS-CoV-2, Spike Glycoprotein, Coronavirus, Vaccination, Immune Evasion, Neutralizing, 631/326/596/4130, Syncytium, Multidisciplinary, Cell fusion, biology, article, Vaccine efficacy, 631/250/254, Virology, Spike Glycoprotein, Coronavirus, 13/31, biology.protein, Antibody, Infection
Abstract: The B.1.617.2 (Delta) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first identified in the state of Maharashtra in late 2020 and spread throughout India, outcompeting pre-existing lineages including B.1.617.1 (Kappa) and B.1.1.7 (Alpha)1. In vitro, B.1.617.2 is sixfold less sensitive to serum neutralizing antibodies from recovered individuals, and eightfold less sensitive to vaccine-elicited antibodies, compared with wild-type Wuhan-1 bearing D614G. Serum neutralizing titres against B.1.617.2 were lower in ChAdOx1 vaccinees than in BNT162b2 vaccinees. B.1.617.2 spike pseudotyped viruses exhibited compromised sensitivity to monoclonal antibodies to the receptor-binding domain and the amino-terminal domain. B.1.617.2 demonstrated higher replication efficiency than B.1.1.7 in both airway organoid and human airway epithelial systems, associated with B.1.617.2 spike being in a predominantly cleaved state compared with B.1.1.7 spike. The B.1.617.2 spike protein was able to mediate highly efficient syncytium formation that was less sensitive to inhibition by neutralizing antibody, compared with that of wild-type spike. We also observed that B.1.617.2 had higher replication and spike-mediated entry than B.1.617.1, potentially explaining the B.1.617.2 dominance. In an analysis of more than 130 SARS-CoV-2-infected health care workers across three centres in India during a period of mixed lineage circulation, we observed reduced ChAdOx1 vaccine effectiveness against B.1.617.2 relative to non-B.1.617.2, with the caveat of possible residual confounding. Compromised vaccine efficacy against the highly fit and immune-evasive B.1.617.2 Delta variant warrants continued infection control measures in the post-vaccination era., A study of SARS-CoV-2 variants examining their transmission, infectivity, and potential resistance to therapies provides insights into the biology of the Delta variant and its role in the global pandemic.
Published: 2022

32. Development of a colorimetric assay for the detection of SARS-CoV-2 3CLpro activity

Author: Garland, Gavin D., primary, Harvey, Robert F., additional, Mulroney, Thomas E., additional, Monti, Mie, additional, Fuller, Stewart, additional, Haigh, Richard, additional, Gerber, Pehuén Pereyra, additional, Barer, Michael R., additional, Matheson, Nicholas J., additional, and Willis, Anne E., additional
Published: 2022
Full Text: View/download PDF

33. B cell receptor repertoire kinetics after SARS-CoV-2 infection and vaccination

Author: Kotagiri, Prasanti, Mescia, Federica, Rae, William M., Bergamaschi, Laura, Tuong, Zewen K., Turner, Lorinda, Hunter, Kevin, Gerber, Pehuén P., Hosmillo, Myra, Cambridge Institute of Therapeutic Immunology and Infectious Disease-National Institute of Health Research (CITIID-NIHR) COVID-19 BioResource Collaboration, Hess, Christoph, Clatworthy, Menna R., Goodfellow, Ian G., Matheson, Nicholas J., McKinney, Eoin F., Wills, Mark R., Gupta, Ravindra K., Bradley, John R., and Smith, Kenneth G.C.
Abstract: B cells are important in immunity to both severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection and vaccination, but B cell receptor (BCR) repertoire development in these contexts has not been compared. We analyze serial samples from 171 SARS-CoV-2-infected individuals and 63 vaccine recipients and find the global BCR repertoire differs between them. Following infection, immunoglobulin (Ig)G1/3 and IgA1 BCRs increase, somatic hypermutation (SHM) decreases, and, in severe disease, IgM and IgA clones are expanded. In contrast, after vaccination, the proportion of IgD/M BCRs increase, SHM is unchanged, and expansion of IgG clones is prominent. VH1-24, which targets the N-terminal domain (NTD) and contributes to neutralization, is expanded post infection except in the most severe disease. Infection generates a broad distribution of SARS-CoV-2-specific clones predicted to target the spike protein, while a more focused response after vaccination mainly targets the spike's receptor-binding domain. Thus, the nature of SARS-CoV-2 exposure differentially affects BCR repertoire development, potentially informing vaccine strategies., Cell Reports, 38 (7), ISSN:2666-3864, ISSN:2211-1247
Published: 2022
Full Text: View/download PDF

34. Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection

Author: Jones, Nick K, Rivett, Lucy, Seaman, Shaun, Samworth, Richard J, Warne, Ben, Workman, Chris, Ferris, Mark, Wright, Jo, Quinnell, Natalie, Shaw, Ashley, Cambridge COVID-19 Collaboration, Goodfellow, Ian G, Lehner, Paul J, Howes, Rob, Wright, Giles, Matheson, Nicholas J, Weekes, Michael P, Amory, Amy, Baker, Stephen, Bateman, Emma, Begum, Aklima, Begum, Moushima, Bradley, John, Brennan, Michael, Burn, Helen, Crofts, Caroline, Chaudhry, Afzal, Chaudhry, Yasmin, Cooper, Daniel J, Dawson, Sharon, Dougan, Gordon, Feather, Renny, Free, Louise, Friel, Katie, Gildea, Claire, Georgana, Iliana, Grimwade, Lizz, Gupta, Ravi, Hall, Susan, Hannan, Sophie, Hayes, James, Hosaja, Aleksandra, Hosmillo, Myra, Izuagbe, Rhys, Jahun, Aminu, James, Lidia, Jardin, Jill, Kingston, Nathalie, Lear, Sara, Lyons, Paul A, Maxwell, Patrick H, Mott, Sue, Mugavin, Sarah, Mwiya, Joyce, Peacock, Sharon, Nallattil, Ravi Prakash, Oloyede, Kazeem, Ouwehand, Willem H, Page, Elle, Perez, Marina, Raine, Tim, Routledge, Matthew, Saunders, Caroline, Smith, Kenneth GC, Sparkes, Dominic, Stafford, Maria, Summers, Charlotte, Tatsi, Despiona, Thaventhiran, James ED, Thomas Johnson, Sharon, Török, M Estée, Toshner, Mark, Turner, Lesley, Wall, Kate, Watson, Karis, Jones, Nick K [0000-0003-4475-7761], Rivett, Lucy [0000-0002-2781-9345], Goodfellow, Ian G [0000-0002-9483-510X], Lehner, Paul J [0000-0001-9383-1054], Matheson, Nicholas J [0000-0002-3318-1851], Weekes, Michael P [0000-0003-3196-5545], and Apollo - University of Cambridge Repository
Subjects: Microbiology and Infectious Disease, Epidemiology and Global Health, SARS-CoV-2, COVID-19, asymptomatic, BNT162b2, Pfizer-BioNTech, Research Advance, vaccination, Human
Abstract: The BNT162b2 mRNA COVID-19 vaccine (Pfizer-BioNTech) is being utilised internationally for mass COVID-19 vaccination. Evidence of single-dose protection against symptomatic disease has encouraged some countries to opt for delayed booster doses of BNT162b2, but the effect of this strategy on rates of asymptomatic SARS-CoV-2 infection remains unknown. We previously demonstrated frequent pauci- and asymptomatic SARS-CoV-2 infection amongst healthcare workers (HCWs) during the UK’s first wave of the COVID-19 pandemic, using a comprehensive PCR-based HCW screening programme (Rivett et al., 2020; Jones et al., 2020). Here, we evaluate the effect of first-dose BNT162b2 vaccination on test positivity rates and find a fourfold reduction in asymptomatic infection amongst HCWs ≥12 days post-vaccination. These data provide real-world evidence of short-term protection against asymptomatic SARS-CoV-2 infection following a single dose of BNT162b2 vaccine, suggesting that mass first-dose vaccination will reduce SARS-CoV-2 transmission, as well as the burden of COVID-19 disease.
Published: 2021
Full Text: View/download PDF

35. A protease-activatable luminescent biosensor and reporter cell line for authentic SARS-CoV-2 infection

Author: Gerber, Pehuén Pereyra, primary, Duncan, Lidia M., additional, Greenwood, Edward JD, additional, Marelli, Sara, additional, Naamati, Adi, additional, Teixeira-Silva, Ana, additional, Crozier, Thomas WM, additional, Gabaev, Ildar, additional, Zhan, Jun R., additional, Mulroney, Thomas E., additional, Horner, Emily C., additional, Doffinger, Rainer, additional, Willis, Anne E., additional, Thaventhiran, James ED, additional, Protasio, Anna V., additional, and Matheson, Nicholas J., additional
Published: 2022
Full Text: View/download PDF

36. Early intervention in acute renal failure

Author: Gleadle, Jonathan M, Matheson, Nicholas J, Irani, Sarosh R, and Irani, Anushka
Published: 2006

37. Efficacy of FFP3 respirators for prevention of SARS-CoV-2 infection in healthcare workers

Author: Ferris, Mark, primary, Ferris, Rebecca, primary, Workman, Chris, additional, O'Connor, Eoin, additional, Enoch, David A, additional, Goldesgeyme, Emma, additional, Quinnell, Natalie, additional, Patel, Parth, additional, Wright, Jo, additional, Martell, Geraldine, additional, Moody, Christine, additional, Shaw, Ashley, additional, Illingworth, Christopher JR, additional, Matheson, Nicholas J, additional, and Weekes, Michael P, additional
Published: 2021
Full Text: View/download PDF

38. Author response: Efficacy of FFP3 respirators for prevention of SARS-CoV-2 infection in healthcare workers

Author: Ferris, Mark, primary, Ferris, Rebecca, primary, Workman, Chris, additional, O'Connor, Eoin, additional, Enoch, David A, additional, Goldesgeyme, Emma, additional, Quinnell, Natalie, additional, Patel, Parth, additional, Wright, Jo, additional, Martell, Geraldine, additional, Moody, Christine, additional, Shaw, Ashley, additional, Illingworth, Christopher JR, additional, Matheson, Nicholas J, additional, and Weekes, Michael P, additional
Published: 2021
Full Text: View/download PDF

39. Mass testing of university students for covid-19

Author: Matheson, Nicholas J, primary, Warne, Ben, additional, Weekes, Michael P, additional, and Maxwell, Patrick H, additional
Published: 2021
Full Text: View/download PDF

40. Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2

Author: Collier, Dami A., Ferreira, Isabella A. T. M., Kotagiri, Prasanti, Datir, Rawlings P., Lim, Eleanor Y., Touizer, Emma, Meng, Bo, Abdullahi, Adam, Elmer, Anne, Kingston, Nathalie, Graves, Barbara, Le Gresley, Emma, Caputo, Daniela, Bergamaschi, Laura, Smith, Kenneth G. C., Bradley, John R., Ceron-Gutierrez, Lourdes, Cortes-Acevedo, Paulina, Barcenas-Morales, Gabriela, Linterman, Michelle A., McCoy, Laura E., Davis, Chris, Thomson, Emma, McKinney, Eoin, Doffinger, Rainer, Wills, Mark, Gupta, Ravindra K., Baker, Stephen, Dougan, Gordon, Hess, Christoph, Lehner, Paul J., Lyons, Paul A., Matheson, Nicholas J., Owehand, Willem H., Saunders, Caroline, Summers, Charlotte, Thaventhiran, James E. D., Toshner, Mark, Weekes, Michael P., Maxwell, Patrick, Shaw, Ashley, Bucke, Ashlea, Calder, Jo, Canna, Laura, Domingo, Jason, Fuller, Stewart, Harris, Julie, Hewitt, Sarah, Kennet, Jane, Jose, Sherly, Kourampa, Jenny, Meadows, Anne, O’Brien, Criona, Price, Jane, Publico, Cherry, Rastall, Rebecca, Ribeiro, Carla, Rowlands, Jane, Ruffolo, Valentina, Tordesillas, Hugo, Bullman, Ben, Dunmore, Benjamin J., Fawke, Stuart, Gräf, Stefan, Hodgson, Josh, Huang, Christopher, Hunter, Kelvin, Jones, Emma, Legchenko, Ekaterina, Matara, Cecilia, Martin, Jennifer, Mescia, Federica, O’Donnell, Ciara, Pointon, Linda, Pond, Nicole, Shih, Joy, Sutcliffe, Rachel, Tilly, Tobias, Treacy, Carmen, Tong, Zhen, Wood, Jennifer, Wylot, Marta, Betancourt, Ariana, Bower, Georgie, Cossetti, Chiara, De Sa, Aloka, Epping, Madeline, Gleadall, Nick, Grenfell, Richard, Hinch, Andrew, Huhn, Oisin, Jackson, Sarah, Jarvis, Isobel, Krishna, Ben, Lewis, Daniel, Marsden, Joe, Nice, Francesca, Okecha, Georgina, Omarjee, Ommar, Perera, Marianne, Potts, Martin, Richoz, Nathan, Romashova, Veronika, Yarkoni, Natalia Savinykh, Sharma, Rahul, Stefanucci, Luca, Stephens, Jonathan, Strezlecki, Mateusz, Turner, Lori, D. D. De Bie, Eckart M., Bunclark, Katherine, Josipovic, Masa, Mackay, Michael, Michael, Alice, Rossi, Sabrina, Selvan, Mayurun, Spencer, Sarah, Yong, Cissy, Ansaripour, Ali, Mwaura, Lucy, Patterson, Caroline, Polwarth, Gary, Polgarova, Petra, Di Stefano, Giovanni, Fahey, Codie, Michel, Rachel, Bong, Sze-How, Coudert, Jerome D., Holmes, Elaine, Allison, John, Butcher, Helen, Clapham-Riley, Debbie, Dewhurst, Eleanor, Furlong, Anita, Gray, Jennifer, Ivers, Tasmin, Kasanicki, Mary, Linger, Rachel, Meloy, Sarah, Muldoon, Francesca, Ovington, Nigel, Papadia, Sofia, Phelan, Isabel, Stark, Hannah, Stirrups, Kathleen E., Townsend, Paul, Walker, Neil, Webster, Jennifer, Collier, Dami A. [0000-0001-5446-4423], Datir, Rawlings P. [0000-0003-0521-2144], Smith, Kenneth G. C. [0000-0003-3829-4326], Linterman, Michelle A. [0000-0001-6047-1996], McCoy, Laura E. [0000-0001-9503-7946], Thomson, Emma [0000-0003-1482-0889], Lyons, Paul A. [0000-0001-7035-8997], Gupta, Ravindra K. [0000-0001-9751-1808], and Apollo - University of Cambridge Repository
Subjects: article, 13/106, 38/39, 631/250/2152/2153/1291, 631/326/596/4130, 38
Abstract: Although two-dose mRNA vaccination provides excellent protection against SARS-CoV-2, there is little information about vaccine efficacy against variants of concern (VOC) in individuals above eighty years of age1. Here we analysed immune responses following vaccination with the BNT162b2 mRNA vaccine2 in elderly participants and younger healthcare workers. Serum neutralization and levels of binding IgG or IgA after the first vaccine dose were lower in older individuals, with a marked drop in participants over eighty years old. Sera from participants above eighty showed lower neutralization potency against the B.1.1.7 (Alpha), B.1.351 (Beta) and P.1. (Gamma) VOC than against the wild-type virus and were more likely to lack any neutralization against VOC following the first dose. However, following the second dose, neutralization against VOC was detectable regardless of age. The frequency of SARS-CoV-2 spike-specific memory B cells was higher in elderly responders (whose serum showed neutralization activity) than in non-responders after the first dose. Elderly participants showed a clear reduction in somatic hypermutation of class-switched cells. The production of interferon-γ and interleukin-2 by SARS-CoV-2 spike-specific T cells was lower in older participants, and both cytokines were secreted primarily by CD4 T cells. We conclude that the elderly are a high-risk population and that specific measures to boost vaccine responses in this population are warranted, particularly where variants of concern are circulating.
Published: 2021
Full Text: View/download PDF

41. Foundation Year For Newly Qualified Doctors

Author: Velineni, Rahul, Sinha, Shrilay, Toram, Satya S., Matheson, Nicholas J., Burns, Alex, and Henderson, Katherine
Published: 2005

42. Guidelines on neuraminidase inhibitors in children are not supported by evidence

Author: Symmonds, Mkael, Matheson, Nicholas J, and Harnden, Anthony
Published: 2004

43. Screening of healthcare workers for SARS-CoV-2 highlights the role of asymptomatic carriage in COVID-19 transmission

Author: Rivett, Lucy, Sridhar, Sushmita, Sparkes, Dominic, Routledge, Matthew, Jones, Nick K, Forrest, Sally, Young, Jamie, Pereira-Dias, Joana, Hamilton, William L, Ferris, Mark, Torok, M Estee, Meredith, Luke, Collaboration, The CITIID-NIHR COVID-19 BioResource, Curran, Martin D, Fuller, Stewart, Chaudhry, Afzal, Shaw, Ashley, Samworth, Richard J, Bradley, John R, Dougan, Gordon, Smith, Kenneth GC, Lehner, Paul J, Matheson, Nicholas J, Wright, Giles, Goodfellow, Ian G, Baker, Stephen, Weekes, Michael P, Gupta, Ravi, Lyons, Paul A, Toshner, Mark, Warne, Ben, Bartholdson Scott, Josefin, Cormie, Claire, Gill, Harmeet, Kean, Iain, Maes, Mailis, Reynolds, Nicola, Wantoch, Michelle, Caddy, Sarah, Caller, Laura, Feltwell, Theresa, Hall, Grant, Hosmillo, Myra, Houldcroft, Charlotte, Jahun, Aminu, Khokhar, Fahad, Yakovleva, Anna, Butcher, Helen, Caputo, Daniela, Clapham-Riley, Debra, Dolling, Helen, Furlong, Anita, Graves, Barbara, Gresley, Emma Le, Kingston, Nathalie, Papadia, Sofia, Stark, Hannah, Stirrups, Kathleen E, Webster, Jennifer, Calder, Joanna, Harris, Julie, Hewitt, Sarah, Kennet, Jane, Meadows, Anne, Rastall, Rebecca, Brien, Criona O, Price, Jo, Publico, Cherry, Rowlands, Jane, Ruffolo, Valentina, Tordesillas, Hugo, Brookes, Karen, Canna, Laura, Cruz, Isabel, Dempsey, Katie, Elmer, Anne, Escoffery, Naidine, Jones, Heather, Ribeiro, Carla, Saunders, Caroline, Wright, Angela, Nyagumbo, Rutendo, Roberts, Anne, Bucke, Ashlea, Hargreaves, Simone, Johnson, Danielle, Narcorda, Aileen, Read, Debbie, Sparke, Christian, Warboys, Lucy, Lagadu, Kirsty, Mactavous, Lenette, Gould, Tim, Raine, Tim, Mather, Claire, Ramenatte, Nicola, Vallier, Anne-Laure, Kasanicki, Mary, Eames, Penelope-Jane, McNicholas, Chris, Thake, Lisa, Bartholomew, Neil, Brown, Nick, Parmar, Surendra, Zhang, Hongyi, Bowring, Ailsa, Martell, Geraldine, Quinnell, Natalie, Wright, Jo, Murphy, Helen, Dunmore, Benjamin J, Legchenko, Ekaterina, Gräf, Stefan, Huang, Christopher, Hodgson, Josh, Hunter, Kelvin, Martin, Jennifer, Mescia, Federica, O'Donnell, Ciara, Pointon, Linda, Shih, Joy, Sutcliffe, Rachel, Tilly, Tobias, Tong, Zhen, Treacy, Carmen, Wood, Jennifer, Bergamaschi, Laura, Betancourt, Ariana, Bowyer, Georgie, De Sa, Aloka, Epping, Maddie, Hinch, Andrew, Huhn, Oisin, Jarvis, Isobel, Lewis, Daniel, Marsden, Joe, McCallum, Simon, Nice, Francescsa, Rivett, Lucy [0000-0002-2781-9345], Lehner, Paul J [0000-0001-9383-1054], Matheson, Nicholas J [0000-0002-3318-1851], Goodfellow, Ian G [0000-0002-9483-510X], Weekes, Michael P [0000-0003-3196-5545], and Apollo - University of Cambridge Repository
Subjects: Epidemiology and Global Health, SARS-CoV-2, infectious disease, education, occupational health, virus diseases, COVID-19, Human Biology and Medicine, Research Article, virology, emerging pathogens, Human, Virus
Abstract: Funder: Addenbrooke's Charitable Trust, Cambridge University Hospitals; FundRef: http://dx.doi.org/10.13039/501100002927, Significant differences exist in the availability of healthcare worker (HCW) SARS-CoV-2 testing between countries, and existing programmes focus on screening symptomatic rather than asymptomatic staff. Over a 3 week period (April 2020), 1032 asymptomatic HCWs were screened for SARS-CoV-2 in a large UK teaching hospital. Symptomatic staff and symptomatic household contacts were additionally tested. Real-time RT-PCR was used to detect viral RNA from a throat+nose self-swab. 3% of HCWs in the asymptomatic screening group tested positive for SARS-CoV-2. 17/30 (57%) were truly asymptomatic/pauci-symptomatic. 12/30 (40%) had experienced symptoms compatible with coronavirus disease 2019 (COVID-19)>7 days prior to testing, most self-isolating, returning well. Clusters of HCW infection were discovered on two independent wards. Viral genome sequencing showed that the majority of HCWs had the dominant lineage B∙1. Our data demonstrates the utility of comprehensive screening of HCWs with minimal or no symptoms. This approach will be critical for protecting patients and hospital staff.
Published: 2020
Full Text: View/download PDF

44. Effective control of SARS-CoV-2 transmission between healthcare workers during a period of diminished community prevalence of COVID-19

Author: Jones, Nick K, Rivett, Lucy, Sparkes, Dominic, Forrest, Sally, Sridhar, Sushmita, Young, Jamie, Pereira-Dias, Joana, Cormie, Claire, Gill, Harmeet, Reynolds, Nicola, Wantoch, Michelle, Routledge, Matthew, Warne, Ben, Levy, Jack, Córdova Jiménez, William David, Samad, Fathima Nisha Begum, McNicholas, Chris, Ferris, Mark, Gray, Jane, Gill, Michael, Collaboration, The CITIID-NIHR COVID-19 BioResource, Curran, Martin D, Fuller, Stewart, Chaudhry, Afzal, Shaw, Ashley, Bradley, John R, Hannon, Gregory J, Goodfellow, Ian G, Dougan, Gordon, Smith, Kenneth GC, Wright, Giles, Baker, Stephen, Weekes, Michael P, Bradley, John, Goodfellow, Ian, Gupta, Ravi, Lehner, Paul J, Lyons, Paul A, Matheson, Nicholas J, Torok, M Estee, Toshner, Mark, Jones, Nick K [0000-0003-4475-7761], Sridhar, Sushmita [0000-0001-7453-7482], Hannon, Gregory J [0000-0003-4021-3898], Goodfellow, Ian G [0000-0002-9483-510X], Lehner, Paul J [0000-0001-9383-1054], Matheson, Nicholas J [0000-0002-3318-1851], Weekes, Michael P [0000-0003-3196-5545], and Apollo - University of Cambridge Repository
Subjects: Epidemiology and Global Health, SARS-CoV-2, infectious disease, occupational health, virus diseases, COVID-19, Research Advance, Human Biology and Medicine, virology, emerging pathogens, Human
Abstract: Funder: Addenbrooke's Charitable Trust, Cambridge University Hospitals; FundRef: http://dx.doi.org/10.13039/501100002927, Funder: National Institute for Health Research; FundRef: http://dx.doi.org/10.13039/501100000272, Previously, we showed that 3% (31/1032)of asymptomatic healthcare workers (HCWs) from a large teaching hospital in Cambridge, UK, tested positive for SARS-CoV-2 in April 2020. About 15% (26/169) HCWs with symptoms of coronavirus disease 2019 (COVID-19) also tested positive for SARS-CoV-2 (Rivett et al., 2020). Here, we show that the proportion of both asymptomatic and symptomatic HCWs testing positive for SARS-CoV-2 rapidly declined to near-zero between 25th April and 24th May 2020, corresponding to a decline in patient admissions with COVID-19 during the ongoing UK ‘lockdown’. These data demonstrate how infection prevention and control measures including staff testing may help prevent hospitals from becoming independent ‘hubs’ of SARS-CoV-2 transmission, and illustrate how, with appropriate precautions, organizations in other sectors may be able to resume on-site work safely.
Published: 2020

45. Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B.1.1.7

Author: Meng, Bo, Kemp, Steven A, Papa, Guido, Datir, Rawlings, Ferreira, Isabella ATM, Marelli, Sara, Harvey, William T, Lytras, Spyros, Mohamed, Ahmed, Gallo, Giulia, Thakur, Nazia, Collier, Dami A, Mlcochova, Petra, COVID-19 Genomics UK (COG-UK) Consortium, Duncan, Lidia M, Carabelli, Alessandro M, Kenyon, Julia C, Lever, Andrew M, De Marco, Anna, Saliba, Christian, Culap, Katja, Cameroni, Elisabetta, Matheson, Nicholas J, Piccoli, Luca, Corti, Davide, James, Leo C, Robertson, David L, Bailey, Dalan, Gupta, Ravindra K, Kemp, Steven [0000-0001-7077-6793], Datir, Rawlings [0000-0003-0521-2144], Mlcochova, Petra [0000-0001-6908-9363], Carabelli, Alessandro [0000-0003-3625-4021], Matheson, Nicholas [0000-0002-3318-1851], Gupta, Ravindra [0000-0001-9751-1808], and Apollo - University of Cambridge Repository
Subjects: Medical Physiology, Antibodies, Viral, Antibodies, Cell Line, resistance, COVID-19 Genomics UK (COG-UK) Consortium, Recurrence, spike mutation, Chlorocebus aethiops, Animals, Humans, neutralizing antibodies, Viral, deletion, B.1.1.7, Neutralizing, Lung, Pandemics, Vero Cells, Phylogeny, Immune Evasion, SARS-CoV-2, infectivity, COVID-19, Pneumonia, Antibodies, Neutralizing, Spike Glycoprotein, Coronavirus, body regions, Infectious Diseases, Emerging Infectious Diseases, Good Health and Well Being, HEK293 Cells, Alpha variant, Mutation, Spike Glycoprotein, Coronavirus, antibody escape, Biochemistry and Cell Biology, Protein Binding
Abstract: We report severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike ΔH69/V70 in multiple independent lineages, often occurring after acquisition of receptor binding motif replacements such as N439K and Y453F, known to increase binding affinity to the ACE2 receptor and confer antibody escape. Invitro, we show that, although ΔH69/V70 itself is not an antibody evasion mechanism, it increases infectivity associated with enhanced incorporation of cleaved spike into virions. ΔH69/V70 is able to partially rescue infectivity of spike proteins that have acquired N439K and Y453F escape mutations by increased spike incorporation. In addition, replacement of the H69 and V70 residues in the Alpha variant B.1.1.7 spike (where ΔH69/V70 occurs naturally) impairs spike incorporation and entry efficiency of the B.1.1.7 spike pseudotyped virus. Alpha variant B.1.1.7 spike mediates faster kinetics of cell-cell fusion than wild-type Wuhan-1 D614G, dependent on ΔH69/V70. Therefore, as ΔH69/V70 compensates for immune escape mutations that impair infectivity, continued surveillance for deletions with functional effects is warranted.
Published: 2021

46. Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the variant of concern lineage B.1.1.7

Author: Meng, Bo, Kemp, Steven A., Papa, Guido, Datir, Rawlings, Ferreira, Isabella ATM., Marelli, Sara, Harvey, William T., Lytras, Spyros, Mohamed, Ahmed, Gallo, Giulia, Thakur, Nazia, Collier, Dami A., Mlcochova, Petra, Duncan, Lidia M., Carabelli, Alessandro M., Kenyon, Julia C., Lever, Andrew M., De Marco, Anna, Saliba, Christian, Culap, Katja, Cameroni, Elisabetta, Matheson, Nicholas J., Piccoli, Luca, Corti, Davide, James, Leo C., Robertson, David L., Bailey, Dalan, and Gupta, Ravindra K.
Subjects: body regions
Abstract: We report SARS-CoV-2 spike ΔH69/V70 in multiple independent lineages, often occurring after acquisition of the receptor binding motif replacements such as N439K and Y453F known to increase binding affinity to the ACE2 receptor and confer antibody escape. In vitro, we show that whilst ΔH69/V70 itself is not an antibody evasion mechanism, it increases infectivity associated with enhanced incorporation of cleaved spike into virions. ΔH69/V70 is able to partially rescue infectivity of S proteins that have acquired N439K and Y453F escape mutations by increased spike incorporation. In addition, replacement of H69 and V70 residues in B.1.1.7 spike (where ΔH69/V70 naturally occurs) impairs spike incorporation and entry efficiency of B.1.1.7 spike pseudotyped virus. B.1.1.7 spike mediates faster kinetics of cell-cell fusion than wild type Wuhan-1 D614G, dependent on ΔH69/V70. Therefore, as ΔH69/V70 compensates for immune escape mutations that impair infectivity, continued surveillance for deletions with functional effects is warranted.
Published: 2021

47. Single-cell multi-omics analysis of the immune response in COVID-19

Author: Stephenson, Emily, Reynolds, Gary, Botting, Rachel A., Calero-Nieto, Fernando J., Morgan, Michael D., Tuong, Zewen Kelvin, Bach, Karsten, Sungnak, Waradon, Worlock, Kaylee B., Yoshida, Masahiro, Kumasaka, Natsuhiko, Kania, Katarzyna, Engelbert, Justin, Olabi, Bayanne, Spegarova, Jarmila Stremenova, Wilson, Nicola K., Mende, Nicole, Jardine, Laura, Gardner, Louis C. S., Goh, Issac, Horsfall, Dave, McGrath, Jim, Webb, Simone, Mather, Michael W., Lindeboom, Rik G. H., Dann, Emma, Huang, Ni, Polanski, Krzysztof, Prigmore, Elena, Gothe, Florian, Scott, Jonathan, Payne, Rebecca P., Baker, Kenneth F., Hanrath, Aidan T., Schim Van Der Loeff, Ina C. D., Barr, Andrew S., Sanchez-Gonzalez, Amada, Bergamaschi, Laura, Mescia, Federica, Barnes, Josephine L., Kilich, Eliz, De Wilton, Angus, Saigal, Anita, Saleh, Aarash, Janes, Sam M., Smith, Claire M., Gopee, Nusayhah, Wilson, Caroline, Coupland, Paul, Coxhead, Jonathan M., Kiselev, Vladimir Yu, Van Dongen, Stijn, Bacardit, Jaume, King, Hamish W., Rostron, Anthony J., Simpson, A. John, Hambleton, Sophie, Laurenti, Elisa, Lyons, Paul A., Meyer, Kerstin B., Nikolić, Marko Z., Duncan, Christopher J. A., Teichmann, Sarah A., Clatworthy, Menna R., Marioni, John C., Göttgens, Berthold, Haniffa, Muzlifah, Baker, Stephen, Bradley, John R., Dougan, Gordon, Goodfellow, Ian G., Gupta, Ravindra K., Hess, Christoph, Kingston, Nathalie, Lehner, Paul J., Matheson, Nicholas J., Owehand, Willem H., Saunders, Caroline, Smith, Kenneth G. C., Summers, Charlotte, Thaventhiran, James E. D., Toshner, Mark, Weekes, Michael P., Bucke, Ashlea, Calder, Jo, Canna, Laura, Domingo, Jason, Elmer, Anne, Fuller, Stewart, Harris, Julie, Hewitt, Sarah, Kennet, Jane, Jose, Sherly, Kourampa, Jenny, Meadows, Anne, O’Brien, Criona, Price, Jane, Publico, Cherry, Rastall, Rebecca, Ribeiro, Carla, Rowlands, Jane, Ruffolo, Valentina, Tordesillas, Hugo, Bullman, Ben, Dunmore, Benjamin J., Fawke, Stuart, Gräf, Stefan, Hodgson, Josh, Huang, Christopher, Hunter, Kelvin, Jones, Emma, Legchenko, Ekaterina, Matara, Cecilia, Martin, Jennifer, O’Donnell, Ciara, Pointon, Linda, Pond, Nicole, Shih, Joy, Sutcliffe, Rachel, Tilly, Tobias, Treacy, Carmen, Tong, Zhen, Wood, Jennifer, Wylot, Marta, Betancourt, Ariana, Bower, Georgie, De Sa, Aloka, Epping, Madeline, Huhn, Oisin, Jackson, Sarah, Jarvis, Isobel, Marsden, Jimmy, Nice, Francesca, Okecha, Georgina, Omarjee, Ommar, Perera, Marianne, Richoz, Nathan, Sharma, Rahul, Turner, Lori, De Bie, Eckart M. D. D., Bunclark, Katherine, Josipovic, Masa, Mackay, Michael, Michael, Alice, Rossi, Sabrina, Selvan, Mayurun, Spencer, Sarah, Yong, Cissy, Ansaripour, Ali, Mwaura, Lucy, Patterson, Caroline, Polwarth, Gary, Polgarova, Petra, Stefano, Giovanni Di, Allison, John, Butcher, Helen, Caputo, Daniela, Clapham-Riley, Debbie, Dewhurst, Eleanor, Furlong, Anita, Graves, Barbara, Gray, Jennifer, Ivers, Tasmin, Kasanicki, Mary, Gresley, Emma Le, Linger, Rachel, Meloy, Sarah, Muldoon, Francesca, Ovington, Nigel, Papadia, Sofia, Phelan, Isabel, Stark, Hannah, Stirrups, Kathleen E., Townsend, Paul, Walker, Neil, Webster, Jennifer, Calero-Nieto, Fernando J. [0000-0003-3358-8253], Morgan, Michael D. [0000-0003-0757-0711], Tuong, Zewen Kelvin [0000-0002-6735-6808], Sungnak, Waradon [0000-0002-0136-4960], Yoshida, Masahiro [0000-0002-3521-5322], Kumasaka, Natsuhiko [0000-0002-3557-0375], Spegarova, Jarmila Stremenova [0000-0002-0710-9266], Wilson, Nicola K. [0000-0003-0865-7333], Mende, Nicole [0000-0002-5078-2333], Gardner, Louis C. S. [0000-0002-7200-978X], Goh, Issac [0000-0002-6397-3518], Horsfall, Dave [0000-0002-8086-812X], Webb, Simone [0000-0003-3058-8952], Mather, Michael W. [0000-0001-7972-7111], Lindeboom, Rik G. H. [0000-0002-3660-504X], Dann, Emma [0000-0002-7400-7438], Polanski, Krzysztof [0000-0002-2586-9576], Payne, Rebecca P. [0000-0002-9037-7367], Baker, Kenneth F. [0000-0002-6735-2911], Schim van der Loeff, Ina C. D. [0000-0003-1196-6196], Barr, Andrew S. [0000-0002-8084-7644], Mescia, Federica [0000-0002-2759-4027], Barnes, Josephine L. [0000-0001-9938-3176], Janes, Sam M. [0000-0002-6634-5939], Smith, Claire M. [0000-0002-8913-0009], Coupland, Paul [0000-0002-2871-3374], Bacardit, Jaume [0000-0002-2692-7205], King, Hamish W. [0000-0001-5972-8926], Rostron, Anthony J. [0000-0002-9336-1723], Simpson, A. John [0000-0003-4731-7294], Hambleton, Sophie [0000-0001-7954-3267], Laurenti, Elisa [0000-0002-9917-9092], Lyons, Paul A. [0000-0001-7035-8997], Meyer, Kerstin B. [0000-0001-5906-1498], Nikolić, Marko Z. [0000-0001-6304-6848], Smith, Kenneth G. C. [0000-0003-3829-4326], Teichmann, Sarah A. [0000-0002-6294-6366], Clatworthy, Menna R. [0000-0002-3340-9828], Marioni, John C. [0000-0001-9092-0852], Göttgens, Berthold [0000-0001-6302-5705], Haniffa, Muzlifah [0000-0002-3927-2084], and Apollo - University of Cambridge Repository
Subjects: 692/699/255/2514, 631/208/514/1949, article, 631/250/232, 631/250/254, 631/326/596/4130
Abstract: Funder: Lister Institute of Preventive Medicine; doi: https://doi.org/10.13039/501100001255, Funder: University College London, Birkbeck MRC Doctoral Training Programme, Funder: The Jikei University School of Medicine, Funder: Action Medical Research (GN2779), Funder: NIHR Clinical Lectureship (CL-2017-01-004), Funder: NIHR (ACF-2018-01-004) and the BMA Foundation, Funder: Chan Zuckerberg Initiative (grant 2017-174169) and from Wellcome (WT211276/Z/18/Z and Sanger core grant WT206194), Funder: UKRI Innovation/Rutherford Fund Fellowship allocated by the MRC and the UK Regenerative Medicine Platform (MR/5005579/1 to M.Z.N.). M.Z.N. and K.B.M. have been funded by the Rosetrees Trust (M944), Funder: Barbour Foundation, Funder: ERC Consolidator and EU MRG-Grammar awards, Funder: Versus Arthritis Cure Challenge Research Grant (21777), and an NIHR Research Professorship (RP-2017-08-ST2-002), Funder: European Molecular Biology Laboratory (EMBL), Analysis of human blood immune cells provides insights into the coordinated response to viral infections such as severe acute respiratory syndrome coronavirus 2, which causes coronavirus disease 2019 (COVID-19). We performed single-cell transcriptome, surface proteome and T and B lymphocyte antigen receptor analyses of over 780,000 peripheral blood mononuclear cells from a cross-sectional cohort of 130 patients with varying severities of COVID-19. We identified expansion of nonclassical monocytes expressing complement transcripts (CD16+C1QA/B/C+) that sequester platelets and were predicted to replenish the alveolar macrophage pool in COVID-19. Early, uncommitted CD34+ hematopoietic stem/progenitor cells were primed toward megakaryopoiesis, accompanied by expanded megakaryocyte-committed progenitors and increased platelet activation. Clonally expanded CD8+ T cells and an increased ratio of CD8+ effector T cells to effector memory T cells characterized severe disease, while circulating follicular helper T cells accompanied mild disease. We observed a relative loss of IgA2 in symptomatic disease despite an overall expansion of plasmablasts and plasma cells. Our study highlights the coordinated immune response that contributes to COVID-19 pathogenesis and reveals discrete cellular components that can be targeted for therapy.
Published: 2021
Full Text: View/download PDF

48. GENE SILENCING: Epigenetic silencing by the HUSH complex mediates position-effect variegation in human cells

Author: Tchasovnikarova, Iva A., Timms, Richard T., Matheson, Nicholas J., Wals, Kim, Antrobus, Robin, Göttgens, Berthold, Dougan, Gordon, Dawson, Mark A., and Lehner, Paul J.
Published: 2015
Full Text: View/download PDF

49. FFP3 respirators protect healthcare workers against infection with SARS-CoV-2

Author: Ferris, Mark, primary, Ferris, Rebecca, additional, Workman, Chris, additional, O'Connor, Eoin, additional, Enoch, David A, additional, Goldesgeyme, Emma, additional, Quinnell, Natalie, additional, Patel, Parth, additional, Wright, Jo, additional, Martell, Geraldine, additional, Moody, Christine, additional, Shaw, Ashley, additional, Illingworth, Christopher J.R., additional, Matheson, Nicholas J., additional, and Weekes, Michael P., additional
Published: 2021
Full Text: View/download PDF

50. Longitudinal analysis reveals that delayed bystander CD8+ T cell activation and early immune pathology distinguish severe COVID-19 from mild disease

Author: Bergamaschi, Laura, primary, Mescia, Federica, additional, Turner, Lorinda, additional, Hanson, Aimee L., additional, Kotagiri, Prasanti, additional, Dunmore, Benjamin J., additional, Ruffieux, Hélène, additional, De Sa, Aloka, additional, Huhn, Oisín, additional, Morgan, Michael D., additional, Gerber, Pehuén Pereyra, additional, Wills, Mark R., additional, Baker, Stephen, additional, Calero-Nieto, Fernando J., additional, Doffinger, Rainer, additional, Dougan, Gordon, additional, Elmer, Anne, additional, Goodfellow, Ian G., additional, Gupta, Ravindra K., additional, Hosmillo, Myra, additional, Hunter, Kelvin, additional, Kingston, Nathalie, additional, Lehner, Paul J., additional, Matheson, Nicholas J., additional, Nicholson, Jeremy K., additional, Petrunkina, Anna M., additional, Richardson, Sylvia, additional, Saunders, Caroline, additional, Thaventhiran, James E.D., additional, Toonen, Erik J.M., additional, Weekes, Michael P., additional, Göttgens, Berthold, additional, Toshner, Mark, additional, Hess, Christoph, additional, Bradley, John R., additional, Lyons, Paul A., additional, and Smith, Kenneth G.C., additional
Published: 2021
Full Text: View/download PDF

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Region

Database

Publisher

258 results on '"Matheson, Nicholas J"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources